Design Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Design Therapeutics, Inc. (DSGN) reported Increase (Decrease) in Deferred Revenue of -$201.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-03-10
- Design Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-12-31 was -$8.00K.
- Design Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-09-30 was -$20.00K.
- Design Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-06-30 was -$31.00K.
- Design Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-03-31 was -$142.00K.
- Design Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2020 was -$201.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$28.00K derived: sum of 2 quarters · filed 2022-03-10 | -$59.00K derived: sum of 3 quarters · filed 2022-03-10 | -$201.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$51.00K derived: sum of 2 quarters · filed 2021-11-09 | -$193.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$173.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$142.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |